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OPEN
ORIGINAL ARTICLE
Kruppel-like factor 4 signals through microRNA-206
to promote tumor initiation and cell survival
C-C Lin1,2,5, SB Sharma1,3,5, MK Farrugia1,3, SL McLaughlin2, RJ Ice1,3, YV Loskutov1,3, EN Pugacheva1,2, KM Brundage2,
D Chen4 and JM Ruppert1,2
Tumor cell heterogeneity poses a major hurdle in the treatment of cancer. Mammary cancer stem-like cells (MaCSCs), or tumor-
initiating cells, are highly tumorigenic sub-populations that have the potential to self-renew and to differentiate. These cells are
clinically important, as they display therapeutic resistance and may contribute to treatment failure and recurrence, but the signaling
axes relevant to the tumorigenic phenotype are poorly defined. The zinc-finger transcription factor Kruppel-like factor 4 (KLF4) is a
pluripotency mediator that is enriched in MaCSCs. KLF4 promotes RAS-extracellular signal-regulated kinase pathway activity and
tumor cell survival in triple-negative breast cancer (TNBC) cells. In this study, we found that both KLF4 and a downstream effector,
microRNA-206 (miR-206), are selectively enriched in the MaCSC fractions of cultured human TNBC cell lines, as well as in the
aldehyde dehydrogenase-high MaCSC sub-population of cells derived from xenografted human mammary carcinomas. The
suppression of endogenous KLF4 or miR-206 activities abrogated cell survival and in vivo tumor initiation, despite having only
subtle effects on MaCSC abundance. Using a combinatorial approach that included in silico as well as loss- and gain-of-function
in vitro assays, we identified miR-206-mediated repression of the pro-apoptotic molecules programmed cell death 4 (PDCD4) and
connexin 43 (CX43/GJA1). Depletion of either of these two miR-206-regulated transcripts promoted resistance to anoikis, a
prominent feature of CSCs, but did not consistently alter MaCSC abundance. Consistent with increased levels of miR-206 in MaCSCs,
the expression of both PDCD4 and CX43 was suppressed in these cells relative to control cells. These results identify miR-206 as an
effector of KLF4-mediated prosurvival signaling in MaCSCs through repression of PDCD4 and CX43. Consequently, our study
suggests that a pluripotency factor exerts prosurvival signaling in MaCSCs, and that antagonism of KLF4-miR-206 signaling may
selectively target the MaCSC niche in TNBC.
Oncogenesis (2015) 4, e155; doi:10.1038/oncsis.2015.8; published online 8 June 2015
INTRODUCTION
Compelling experimental evidence supports the hierarchical
organization of certain human tumor types, including breast
cancer.1–6 These tumors comprise heterogenous mixtures of
tumor cell populations that include cancer stem-like cells (CSCs),
typically defined by their ability to initiate tumors in limiting
dilution assays (that is, tumor-initiating cells, TICs). Furthermore,
CSCs can survive and form tumorspheres in suspension culture,
self-renew and differentiate.7,8 These cells display resistance to
chemotherapy, radiation therapy and other triggers of cell death,
and are thought to contribute to cancer recurrence. Therefore,
CSCs represent an important sub-population for therapeutic
targeting.3,5
In mammary carcinoma, functionally validated CSCs (termed
MaCSCs (mammary CSCs)) have been identified by profiling the
expression of cell surface markers such as PROCR (P) and ESA (E)
and/or by assaying aldehyde dehydrogenase (ALDH) activity.9–12
Despite this insight, the underlying mechanisms that mediate the
MaCSC phenotype are unclear. For regulation of their abundance
and/or their intrinsic properties such as resistance to cell death,
several cellular signaling axes have been implicated including the
WNT, NOTCH, TGFβ and SHH pathways.13–15
A potential mediator of the MaCSC phenotype is the
pluripotency factor Kruppel-like factor 4 (KLF4). This zinc-finger
transcription factor promotes the formation of induced pluripo-
tent stem cells from adult somatic cells and can have both
antitumorigenic and protumorigenic roles in a context-dependent
manner.16–20 The capability of KLF4 to exert protumorigenic
influences may reflect its role as a prosurvival stress response
factor.21–28 In support of a protumorigenic role, KLF4 promotes
epithelial transformation in vitro, escape from RAS-induced
senescence and skin tumor initiation in transgenic mice.16,29,30
Furthermore, loss-of-function studies reveal that KLF4 promotes
cell survival following radiation-induced DNA damage, and
promotes the tumorigenicity of colorectal CSCs-enriched spheroid
cells.26,31
In human breast cancer, KLF4 promoter demethylation and KLF4
protein expression indicate an unfavorable prognosis.32–34 KLF4
expression is positively correlated with tumor size, advanced
grade and stage.35 We previously identified microRNAs, including
microRNA-206 (miR-206) and miR-21, as direct transcriptional
targets of KLF4 that promote RAS-extracellular signal-regulated
kinase (ERK) signaling in triple-negative breast cancer (TNBC)
cells.36,37 Although on its own each miR exerts only subtle
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influences on RAS-ERK pathway activity, the coexpression of
miR-206 and miR-21 potently represses the expression of pathway
inhibitors including RASA1 and SPRED1. Furthermore, miR-206
directly represses KLF4 translation, constituting a feedback loop.36
In this study, we observed elevation of KLF4 and miR-206 in the
P+/E+ and ALDHHigh MaCSC fractions. In TNBC cells, both KLF4 and
miR-206 were critical for cell survival and in vivo tumor initiation.
We identified the tumor-suppressor programmed cell death 4
(PDCD4) as a potential mediator of cell survival by miR-206.
Furthermore, in TNBC cells we demonstrated the miR-206
regulation of a previously validated transcript, the gap junction
protein connexin 43 (CX43/GJA1).38
Consistent with the elevated levels of miR-206 in MaCSCs,
PDCD4 and CX43 levels were decreased. Supporting functional
roles downstream of KLF4 and miR-206, suppression of either
PDCD4 or CX43 led to anoikis resistance, an intrinsic property of
CSCs.7,39–43 Finally, further documenting a prosurvival role,
miR-206 promoted chemoresistance of TNBC cells against
paclitaxel or doxorubicin. Our studies identify KLF4 and miR-206
as functional MaCSC markers that mediate cell survival. Conse-
quently, KLF4 and/or miR-206 may be therapeutically targeted to
selectively cripple MaCSCs in TNBCs.
RESULTS
miR-206 is highly expressed in basal-like breast cancers and
MaCSCs
KLF4 protein levels correlate with an aggressive phenotype in
breast tumors.32,33,35 Similar to KLF4, miR-206 was increased in
human tumors of advanced histological grade (Figure 1a, left
panel). Consistent with studies that identified upregulation of
miR-206 in ER- breast tumors, miR-206 levels were elevated in
TNBCs compared with both ER+ and HER2+ human subgroups
(Figure 1a, right panel).44,45 Enrichment of miR-206 was similarly
observed in murine basal-like mammary tumors (Figure 1b).
Compared with normal mammary tissues or tumors arising in the
luminal MMTV_Neu model,46 we observed upregulation of both
KLF4 and miR-206 in basal-like tumors derived from the C3(1)/SV40
large T antigen (C3(1)/TAg) genetically engineered mouse model
(GEMM) (Figure 1c). These results are consistent with the direct
regulation of miR-206 by KLF4 as previously reported.37
MaCSCs are enriched in the triple-negative subgroup of breast
cancer and are thought to contribute to the aggressive behavior
of these cancers.47–49 Similar to human and murine mammary
carcinoma cells displaying high ALDH activity,11,50–52 MDA-MB-231
TNBC cells displaying the P+/E+ surface marker profile represent
TICs.12 For SUM159PT cells, CD44+/CD24-/ESA+ subset was
previously identified as TICs.53 As the P+ phenotype is a surrogate
for the CD44+/CD24- profile, the P+/E+ SUM159PT cells are likely to
represent MaCSCs.10
We analyzed KLF4 and miR-206 levels in flow-sorted sub-
populations of MDA-MB-231 cells (Figure 1d, left panel).
Compared with non-MaCSCs (that is, P-/E-), miR-206 and KLF4
were increased in the P+/E+ sub-population (Figure 1d, middle
panels). Using P+/E+ cells, we profiled the expression of other
genes associated with stem-like cell phenotypes.9,14,18,19 Com-
pared with P-/E- cells, the expression of CD44, MYC, SOX2, NANOG,
ZEB1 and SNAI2 was upregulated in P+/E+ cells, whereas CD24 and
POU5F1 (OCT3/4) expression were decreased (Figure 1d, right
panel). Similarly, the P+/E+ fraction of SUM159PT cells displayed
elevated levels of KLF4 and miR-206, and showed a similar stem
cell marker profile as the MDA-MB-231 cells (Figure 1e). These
results associate KLF4 and miR-206 with the MaCSC phenotype in
human breast cancer models.
KLF4 and miR-206 are enriched in MaCSCs derived from human
patient-derived xenografts (PDXs) and the C3(1)/TAg GEMM
KLF4 was similarly consistently elevated in lineage-negative
(Lin-)/ALDHHigh MaCSCs isolated from human mammary tumor
tissues that were passaged as PDXs (Figure 2a). miR-206 was
upregulated in three of these four cases. Notably, none of these
tumors displayed an appreciable CD44+/CD24- MaCSC population
(data not shown), consistent with the variable expression of these
markers in patient samples.10,54,55
Tumorspheres are enriched for MaCSCs.7,8 Compared with
cells grown in adherent (two-dimensional (2D)) monolayers,
tumorspheres formed from the Lin- cells of C3(1)/TAg
mammary tumors showed elevated levels of Klf4 and miR-206
(Figure 2b). ALDHHigh cells from other mammary cancer
GEMMs were previously shown to have properties of
MaCSCs.50,52 Similar to the human tumors, Lin-/ALDHHigh cells of
C3(1)/TAg mammary tumors also had increased Klf4 and miR-206
relative to ALDHLow cells (Figure 2c). These results identify KLF4
and miR-206 as MaCSC markers and potential mediators of MaCSC
malignant properties.
KLF4 and miR-206 can promote MaCSC abundance
To determine the effect of KLF4-miR-206 signaling on MaCSC
abundance, we depleted KLF4 in MDA-MB-231 cells using two
distinct lentiviral short hairpin RNA constructs (Figure 3a, left
upper panel). Consistent with previous studies, miR-206 was
suppressed following KLF4 knockdown (Figure 3a, left lower
panel). In addition, P+/E+ cell abundance was modestly decreased
upon KLF4 depletion (Figure 3a, middle and right panels).
Conversely, gain-of-function experiments showed that exogenous
KLF4 promoted both miR-206 levels and the abundance of P+/E+
cells (Figure 3b).
We next sought to determine whether miR-206 could
have a causal role downstream of KLF4 to regulate MaCSC
abundance. As expected, transfection of miR-206 mimic into
MDA-MB-231 cells elevated the miR-206 level as detected
by quantitative reverse transcription and PCR (qRT–PCR;
Figure 3c, left upper panel). In addition, the level of KLF4 was
suppressed, attributed to direct regulation of KLF4 protein
translation by miR-206 (Figure 3c, left lower panel).36 Despite
the reduced levels of KLF4, miR-206-transfected cells displayed
higher P+/E+ cell abundance relative to the control cells (Figure 3c,
right panel). Similar regulation of P+/E+ cell abundance by miR-206
was observed for SUM159PT cells (Figure 3d). These results
establish miR-206 as a potential effector of KLF4 for regulation of
MaCSC abundance.
To determine whether miR-206 can promote the MaCSC
phenotype, we assayed by limiting dilution the capability of
miR-206-transfected MDA-MB-231 cells to initiate tumors in vivo.
Consistent with an increased number of P+/E+ cells, miR-206-
transfected cells formed tumors more efficiently in NOD/SCID-
gamma (NSG) mice compared with control cells (Figure 3e; 2 × 103
cells, P= 0.0022). These results implicate miR-206 as an effector of
KLF4 that promotes tumor initiation.
Endogenous KLF4 and miR-206 promote tumor cell survival and
in vivo tumorigenesis
We next examined the impact of endogenous KLF4-miR-206
signaling on tumor initiation. Depletion of KLF4 reduced the
tumor initiation rate of MDA-MB-231 cells in athymic nude mice
(Figure 4a, left panels). This decrease in tumor incidence was
reflected by the reduced mean tumor volume for all animals
combined (Figure 4a, middle panels). Indicating that the major
effect of KLF4 in this setting is restricted to tumor initiation,
analysis of the tumor-positive subset revealed little difference in
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the tumor growth rate between KLF4-depleted cells and the
control (Figure 4a, right panels).
To study the role of endogenous miR-206 during in vivo
tumorigenesis, we analyzed the tumorigenicity of MDA-MB-231
cells treated by in vitro transfection of anti-sense oligonucleotides
(anti-miR-206). Compared with cells transfected with the control,
anti-miR-206 treatment reduced both tumor incidence and
tumor growth (Figure 4b). As an indicator of successful trans-
fection, KLF4 expression was increased (Figure 4c, left panel).
Effects on tumor growth were not likely attributed to differences
in cell proliferation rates, as anti-miR-206 had little effect
(Figure 4c, right panel).
The critical role of endogenous miR-206 for tumor initiation
following orthotopic injection, despite its minimal effects on cell
proliferation or MaCSC abundance, pointed to a potential
role in regulating cell survival. We therefore assayed for
resistance to cell death following matrix deprivation (anoikis), an
intrinsic property of CSCs.7,39–43 Indeed, consistent with our
previous report that analyzed two human TNBC cell lines,37
anti-miR-206 transfection sensitized several human TNBC
models and a murine basal-like mammary cancer model (that is,
M6 cells) to anoikis (Figure 4d, left panel). Consistent results were
obtained when anoikis was analyzed by poly ADP ribose
polymerase (PARP) cleavage (Figure 4d, right panel). In support
of a prosurvival role for endogenous miR-206, depletion of
KLF4 sensitized TNBC cells to anoikis (Figure 4e). These results
suggest that endogenous KLF4 exerts a prosurvival effect by
induction of miR-206.
Figure 1. KLF4 and miR-206 are selectively expressed in basal-like mammary cancers and in the MaCSC population. (a) miR-206 levels were
analyzed by microarray in 98 primary human breast tumors.91 The Gene Expression Omnibus (GEO) accession number is indicated. (Columns,
mean; bars, s.e.m.; Hist. grade, histologic grade). (b) miR-206 levels were analyzed by microarray in 42 mammary tumors from GEMMs.90 The
GEO accession number is indicated. (c) Klf4 and miR-206 expression was evaluated in normal mammary tissues from FVB/N mice and in
primary tumors arising in the MMTV-Neu and C3(1)/TAg GEMMs. RNA levels were determined by qRT–PCR. (d) MaCSCs were isolated from
MDA-MB-231 cells by sorting using PROCR (P) and ESA (E) as described.12 Transcript levels were analyzed in P+/E+ and P-/E- cells. (e) MaCSCs
were isolated from SUM159PT cells and analyzed similarly as described above for MDA-MB-231 cells.53 For these cells, the P+ profile was used
as a surrogate for CD44+/CD24-.10 (*Po0.05; **Po0.01; ***Po0.001).
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miR-206 suppresses the translation of the tumor-suppressor
PDCD4 and promotes tumor cell survival
We previously reported that RAS-ERK signaling, a prosurvival pathway,
is maintained in TNBC cells by KLF4, in part through its regulation of
miR-206.37 In contrast to the prominent effect of miR-206 on tumor
initiation and cell survival, on its own this miR has only limited effects
on ERK activity.37 We therefore sought to better understand how
endogenous miR-206 can promote anoikis resistance.
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The tumor-suppressor PDCD4 was identified as a potential
miR-206 targeted transcript by multiple miR-target prediction
tools.37,56 PDCD4 is a negative regulator of RAS-ERK-AP1 signaling
and protein translation, and promotes breast cancer cell
apoptosis.57–59 We therefore analyzed PDCD4 as a miR-206-
regulated transcript.
Consistent with regulation of PDCD4 by miR-206, KLF4
depletion in MDA-MB-231 cells increased PDCD4 expression
(Figure 5a, left panel). Similarly, although anti-miR-206 treatment
elevated PDCD4, transfection of miR-206 mimic was suppressive
(Figure 5a, middle and right panels). Direct regulation of PDCD4 by
miR-206 was determined using translational reporter assays.
Fragments of the PDCD4 3′ UTR containing two putative
miR-206-binding sites (denoted WT-A and WT-B; Figure 5b) were
cloned downstream of the open reading frame of firefly luciferase
(luc). Relative to the controls, in MDA-MB-231 cells miR-206 mimic
repressed WT-reporter luc activity by 72%, and anti-miR-206
induced the reporter by 1.9-fold (Figure 5c). Reporter regulation
by miR-206 was abolished by mutation of site WT-A, but not by
mutation of site WT-B, thus identifying site WT-A as a functional
miR-206-binding site (Figure 5b and c). In agreement with
previous studies, PDCD4 depletion in TNBC cells promoted
resistance to anoikis, with little or no effect on 2D proliferation
(Figure 5d).
Consistent with miR-206 regulation of PDCD4 in MaCSCs, the P+/
E+ sub-population of MDA-MB-231 cells exhibited decreased levels
of PDCD4 mRNA and protein compared with non-MaCSCs
(Figure 5e). In TNBC cells, the depletion of PDCD4 was not
sufficient to alter the abundance of the P+/E+ fraction (Figure 5f).
These results appear to support a selective role of PDCD4 for
suppression of tumor cell survival.
miR-206 promotes cell survival by suppressing CX43 in MaCSCs
Our identification of miR-206 regulation of PDCD4 led us to seek
additional targets of this miR that may be important for promoting
cell survival. DIANA-miRPath analysis identifies gap junction
signaling as the top-ranked miR-206-regulated pathway
(P= 2.58 × 10− 6).60 Among the targeted gap junction proteins,
CX43 is a validated miR-206-regulated transcript, as previously
shown in muscle cells.38,61 CX43 is deficient in human breast
tumor cells and MaCSCs, and may exert a tumor-suppressor
role.62–68
Consistent with its regulation by miR-206 in breast cancer cells,
CX43 was increased in KLF4-depleted MDA-MB-231 cells
(Figure 6a, left panel). Similarly, inhibition of miR-206 led to
elevated CX43 levels, and transfection of miR-206 mimic was
suppressive (Figure 6a, middle and right panels). In TNBC cells, the
activity of a translational reporter containing the CX43 3’ UTR was
induced by 1.5-fold following anti-miR-206 treatment, and
suppressed by 53% following transfection of miR-206 mimic
(Figures 6b and c). Supporting the direct regulation of CX43 by
miR-206 in breast tumor cells, mutation of site A (mut206-A)
abolished regulation by miR-206 (Figure 6c). Similar to PDCD4
depletion, suppression of CX43 in TNBC cells promoted resistance
to anoikis, with only subtle effects on cell proliferation (Figure 6d).
Compared with the non-MaCSC fraction, P+/E+ MDA-MB-231
cells displayed lower CX43 mRNA and protein (Figure 6e). These
results support a previous study that reported low CX43
expression in mammary TICs.64 Similarly to PDCD4, knockdown
of CX43 did not consistently alter the P+/E+ cell abundance in
TNBC cells, suggesting a selective role in tumor cell survival (data
not shown).
miR-206 confers chemoresistance in TNBC cells
Consistent with the promotion of cell survival by miR-206 as
determined by anoikis assays, TNBC cells transfected with miR-206
mimic were more resistant to paclitaxel or doxorubicin (Figure 7a).
Furthermore, inhibition of the endogenous miR-206 moderately
sensitized TNBC cells to either agent (Figure 7b). Collectively, these
results link pluripotency factor signaling and the enhanced cell
survival of MaCSCs, supporting roles of KLF4-miR-206 signaling for
breast tumor cell survival, chemoresistance, and tumor initiation
through the repression of PDCD4 and CX43 (Figure 7c).
DISCUSSION
CSCs were first identified in hematopoietic malignancies and
subsequently in solid tumors such as breast cancer.1,3,5,69 Despite
substantial progress, questions remain regarding the relationship
of CSCs to the adult stem cells of normal tissue, and the nature of
the signaling pathways that regulate CSC properties.6 Despite this
uncertainty, it is clear that CSCs represent a highly malignant sub-
population of tumor cells with the capability to resist therapy.3,5
In TNBC cells, KLF4 directly regulates miR-206 transcription, and
depletion of KLF4 consistently results in loss of the vast majority of
miR-206.36,37 In this study, we identified KLF4 and miR-206 as
critical promoters of breast tumor cell survival. Both factors were
preferentially expressed in the MaCSCs purified from 2D cell
culture models of TNBC, from tumorspheres cultured in 3D, from
human PDXs and from primary mouse mammary cancers. As
shown by anti-miR treatment of TNBC cells, endogenous miR-206
directly repressed the translation of the tumor suppressors PDCD4
and CX43 and promoted tumor cell survival, chemoresistance and
in vivo tumor initiation. Immunoblot analysis of MaCSCs revealed
suppressed levels of both PDCD4 and CX43. Mirroring the role of
endogenous miR-206, depletion of each tumor suppressor did not
alter the abundance of CSCs, but instead enhanced tumor cell
survival consistent with previous reports.57,70
miRs can act as critical factors for regulating the abundance
and/or survival of MaCSCs.71–74 In skeletal muscle, miR-206 is
important for repression of PAX7 during stem cell differentiation,
and for muscle regeneration following injury.75–79 In a mammary
cancer context, miR-206 expression is elevated in ER- tumors,
which are enriched for MaCSCs.44,45,47–49 In agreement with
previous studies, we observed that miR-206 is upregulated in
human breast cancers that display a higher grade, in human
TNBCs and in basal-like mammary tumors derived from the C3(1)/
TAg GEMM (Figure 1a and c).
Multiple previous studies have reported that enforced expres-
sion of miR-206 can suppress tumor cell proliferation, invasion or
Figure 2. KLF4 and miR-206 are enriched in ALDHHigh MaCSCs derived from human PDXs and the C3(1)/TAg GEMM. (a) KLF4 and miR-206 levels
were measured in MaCSCs purified in replicate manner from four cases of human mammary carcinoma passaged as xenografts in mice (PDXs).
Purified lineage-negative (Lin-) cells were sorted based on ALDH activity. Fluorescence was analyzed in the presence of the ALDH substrate BAAA
and in presence/absence of the ALDH inhibitor DEAB. The number of xenografted tumors that were analyzed for each case is indicated below
the column data (bars, s.e.m.). n.s., not significant. (b) Lin- cells were isolated from the spontaneous mammary tumors arising in C3(1)/TAg females
(N= 3). Cells from each animal were grown as either adherent monolayers (2D) or in suspension (3D) for 7–10 days. Photomicrographs (left)
depict the morphology of cultured cells. RNA was extracted from 2D or 3D cell cultures and Klf4 and miR-206 levels were determined. (c) Klf4 and
miR-206 levels were measured in the ALDHHigh tumor cells isolated from C3(1)/TAg animals (N= 3, see panel b). ALDHHigh tumor cells derived
from other GEMMs of mammary cancer have been demonstrated to be enriched for TICs50,52 (*Po0.05; **Po0.01; ***Po0.001).
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Figure 3. KLF4 and miR-206 promote MaCSC abundance. (a) MDA-MB-231 cells were transduced with lentiviral vectors expressing KLF4
short hairpin RNAs or a non-targeting control (Ctl). KLF4 protein expression was analyzed by immunoblot (left upper panel). β-Actin served as
a loading control. miR-206 levels were measured by stem loop qRT–PCR (left lower panel). The cell surface marker profile of the transduced
cells was analyzed by flow cytometry (representative scatter plot, middle panel; column data, right panel) (N= 3; bars, s.e.m.). (b) MDA-MB-231
cells were transduced with a retroviral vector encoding KLF4 or empty vector (Ctl). KLF4 and miR-206 levels were analyzed in these cells
(left panels) and the MaCSC abundance was determined by flow cytometry. (c) MDA-MB-231 cells were transfected with either miR-206 mimic
or control oligonucleotides (Ctl) and then analyzed as in the previous panels. (d) SUM159PT cells were transfected with the indicated
miR-mimics and then analyzed as in the previous panels. (e) MDA-MB-231 cells were transfected with miR-206 mimic or control. The indicated
number of cells were mixed with matrigel (50% (vol/vol) in DMEM) and injected into NSG mice. Tumor initiation was measured at 4 weeks
post-injection (**Po0.01; ***Po0.001).
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Figure 4. Endogenous KLF4-miR-206 signaling promotes in vivo tumorigenesis and cell survival. (a) KLF4-depleted and control MDA-MB-231 cells
were orthotopically injected into athymic nude mice. Tumor initiation and tumor size were determined twice per week using digital calipers (right
panels; bars, s.e.m.). (b) MDA-MB-231 cells were transfected with the indicated anti-miRs. Briefly, cells were subjected to sequential transfections
in vitro. At 2 days post-transfection, the cells were injected into athymic nude mice. Tumor incidence and growth were measured as described
above. (c) Residual transfected cells (see panel b) were directly lysed for immunobot analysis (left panel) or else placed in culture for 2D cell
proliferation analysis (right panel, ATPlite; N=6, bars, s.d.). Post-tf, post-transfection. (d) TNBC cells were transfected with either anti-miR-206 or anti-
miR-Ctl and then deprived of matrix for 24 h. Anoikis was measured by Trypan blue exclusion (left panel, N=3, bars, s.d.). In parallel, cells were
assayed by immunoblot analysis of cleaved PARP. Cyclohexamide (CHX) treatment served as a positive control for induction of cell death. (e) Anoikis
was measured in KLF4-depleted MDA-MB-231 cells or control cells by Trypan blue exclusion (N=3, bars, s.d.), by flow cytometric analysis of
propidium iodide (PI)-stained cells (N=3, bars, s.d.), and by analysis of cleaved PARP. n.s., not significant (*Po0.05; **Po0.01; ***Po0.001).
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metastasis.45,80–83 These tumor-suppressor-like effects of miR-206
may result from higher level enforced expression of the
exogenous miR. In this study, suppression of endogenous
miR-206 blocked tumor initiation, and moderate (fivefold)
overexpression of exogenous miR-206 promoted initiation
in a limiting dilution assay. In addition, we observed that
Figure 5. miR-206 suppresses the translation of the tumor-suppressor PDCD4. (a) PDCD4 levels were determined by immunoblot analysis of
the indicated cells. (b) Alignment of the PDCD4 3′UTR region indicating two potential miR-206 binding sites, WT-A and WT-B. The miR-206
seed sequence is underlined. Mutated miR-206 binding sites in the PDCD4 3′ UTR that were utilized in translational reporter assays are
indicated (mt206-A and mt206-B). (c) For analysis of PDCD4 protein translation, MDA-MB-231 cells were co-transfected with reporters in
combination with either miR-mimic (left panel) or anti-miR (right panel). The normalized activity of the reporters relative to empty luc vector
was analyzed 24 h post-transfection (N= 3; bars, s.e.m.). (d) PDCD4 was depleted in the indicated TNBC cells and PDCD4 levels were
determined by immunoblot (upper panels). Cells were suspended in 3D culture for 24 h, and anoikis was measured by flow cytometric analysis
of propidium iodide (PI)-stained cells (middle panels; N= 3; bars, s.e.m.). Following 4 days of 2D culture, the relative cell number of PDCD4-
depleted cells and control cells was determined by the ATPlite assay (N= 6; bars, s.d.). (e) PDCD4 mRNA and protein expression was analyzed
in the indicated sub-populations of TNBC cells. Non-MaCSCs comprises the P+/E- and P-/E- subgroups. The immunoblot data correspond to
one of the three independent experiments that analyzed mRNA levels (N= 3, bars, s.e.m.). (f) MaCSC abundance was analyzed in PDCD4-
depleted TNBC cells and control cells (N= 3; bars, s.d.). n.s., not significant (*Po0.05; **Po0.01; ***Po0.001).
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either exogenous or endogenous miR-206 could promote
malignant properties including tumor cell survival and drug
resistance.
Depletion of endogenous KLF4 suppressed in vivo tumor
initiation by MDA-MB-231 cells in athymic nude mice, yet had
little effect on the growth rate of established tumors. Similarly as
observed for KLF4, transient inhibition of endogenous miR-206 by
anti-miR-206 transfection suppressed tumor initiation in vivo but
did not alter the in vitro proliferation or the MaCSC abundance.
These results suggest that endogenous KLF4 can signal through
miR-206 to promote tumor initiation, probably by impacting cell
survival rather than MaCSC abundance. In contrast, exogenous
KLF4 or miR-206 promoted MaCSC abundance, mirroring the role
of exogenous KLF4 for generation of induced pluripotent stem
cells.18,19 It will be interesting to determine whether miR-206
similarly influences the generation of induced pluripotent
stem cells.
In this study, we have identified endogenous KLF4 and a
downstream effector, miR-206, as functional markers and prosur-
vival factors that are enriched in MaCSCs. Prosurvival signaling by
miR-206 was attributed to direct regulation of PDCD4 and CX43,
and miR-206 enhanced the chemoresistance of TNBC cells.
Figure 6. KLF4-miR-206 signaling suppresses CX43 in MaCSCs. (a) CX43 expression was analyzed in shKLF4 cells and control cells by
immunoblot. Similarly, CX43 expression was analyzed in cells transfected with the indicated miR mimic or anti-miR. (b) Alignment of CX43
3’UTR region, indicating two previously validated miR-206 binding sites, WT-A and WT-B.38 The miR-206 seed sequence is underlined. The
mutation generated in miR-206 binding site A is indicated (mt206-A). (c) For analysis of CX43 protein translation, MDA-MB-231 cells were co-
transfected with reporters in combination with anti-miR (left panel) or miR-mimic (right panel). The normalized activity of the reporters
relative to empty luc vector was analyzed at 24 h post-transfection. (d) CX43 expression was assayed in CX43-depleted TNBC cells and control
cells (upper panels). Cells were suspended in 3D culture for 24 h, and anoikis was measured by flow cytometric analysis of propidium iodide
(PI)-stained cells (middle panels, N= 3; bars, s.e.m.). Following 4 days of 2D culture, the relative cell number of CX43-depleted cells and control
cells was determined by the ATPlite assay (lower panels, N= 6; bars, s.d.). (e) CX43 mRNA and protein expression was analyzed in the indicated
sub-populations of MDA-MB-231 cells (N= 3; bars, s.e.m.). Non-MaCSCs were composed of the P+/E- and P-/E- subgroups. n.s., not significant
(*Po0.05; **Po0.01; ***Po0.001).
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Our study, therefore, provides a rationale for miR-206-directed
antago-miR therapy for the sensitization of the MaCSCs.74,84–88
MATERIALS AND METHODS
Cell lines, cell culture and drug treatments
MDA-MB-231 cells were provided by Katri S Selander (University of
Alabama at Birmingham, AL, USA), SUM159PT cells were provided by Gary
L Johnson (University of North Carolina at Chapel Hill, NC, USA) and M6
mammary carcinoma cells derived from the C3(1)/SV40 TAg mouse model
were provided by Jeffrey E Green (NIH). HCC1143 cells were from ATCC
(Manassas, VA, USA). Cells were maintained as subconfluent monolayers as
previously described.36,37
For chemoresistance experiments, cells were treated with the indicated
doses of paclitaxel (Sigma, St Louis, MO, USA) or doxorubicin (Merck,
Billerica, MA, USA) for 72 h. Cells were treated with cycloheximide (Sigma)
at 20 μg/ml for 24 h. Cell proliferation was determined using the ATPlite
Luminescence Assay System (PerkinElmer, Waltham, MA, USA).
Retroviral transduction
Suppression studies utilized the following pGIPZ lentiviral shRNAmir
plasmids (V2LHS_28277 – shKLF4-1, V3LHS_410934 – shKLF4-2,
V3LHS_411731 – shCX43-1, V3LHS_411733 – shCX43-2, V3LHS_366084 –
shPDCD4-1, V3LHS_366087 – shPDCD4-2; GE Dharmacon/Open Biosys-
tems, Lafayette, CO, USA). The retroviral vector pBABEpuro-HA-KLF4 and
viral transduction was previously described.36 Cells were selected using
puromycin (1 μg/ml).
Plasmid construction
pMIR-REPORT firefly luciferase vector was purchased from Ambion (Austin,
TX, USA). pRL-TK Renilla luc reporter was obtained from Promega (Madison,
WI, USA).
Complementary DNA clones containing fragments of the 3′ UTR of
PDCD4 (clone ID: NM_014456) and CX43/GJA1 were purchased from Open
Biosystems and OriGene (Rockville, MD, USA), respectively.
To construct a WT PDCD4 translational reporter, a 1.7-kb fragment
representing the 3′ UTR was excised using MluI and inserted into MluI-
digested pMIR-REPORT. To construct a WT CX43/GJA1 translational
reporter, a 1.7-kb fragment representing the CX43 3′ UTR was generated
by sequential treatment with EcoRI, Klenow fragment and MluI. This
fragment was inserted into pMIR-REPORT vector that was prepared by
sequential treatment with SacI, Klenow fragment and MluI.
PDCD4 and CX43 reporters with mutation in the miR-seed complemen-
tary regions were generated by PCR mutagenesis. Oligonucleotides are
listed in Supplementary Table S1. WT reporters were mutated so as to
conserve the predicted secondary structure of the 3′ UTR.89 Cloned PCR
products were confirmed by sequence analysis.
Transient transfection and translation reporter assays
The following anti-miR inhibitors (AM) and miR-mimics (PM) were obtained
from Ambion and diluted to 20 μM in nuclease-free water: hsa-miR-206
(AM10409, PM10409), AM-negative control (AM17010), and PM-negative
control (AM17110). Cells were subjected to reverse transfection and, 24 h
later, forward transfection was performed as described.36 At 24 h after the
start of the forward transfection, cell extracts were prepared for expression
studies, or cells were used for phenotypic studies. Translational reporter
assays were performed following just one transfection, at 24 h after the
start of the reverse transfection. Inhibitors/mimics were co-transfected
with reporter plasmids, and Dual-Luciferase Reporter Assays (Promega)
were performed as described.36
Immunoblot analysis and antibodies
Cell extracts for immunoblot analysis were prepared as previously
described.36 PARP cleavage assays were performed as recommended
(Roche, Indianapolis, IN, USA). Following electrophoresis, proteins were
Figure 7. miR-206 promotes chemoresistance in TNBC cells. (a, b) TNBC cells were transfected as indicated. At 48 h post-transfection, cells
were treated with the indicated concentrations of paclitaxel or doxorubicin for a duration of 72 h. Cell viability was determined by the ATPlite
assay (N= 6; bars, s.d.). (c) Schematic of KLF4-miR-206 regulation of PDCD4 and CX43. (**Po0.01; ***Po0.001).
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transferred onto nitrocellulose membranes and probed with the indicated
antibody: KLF4 (Santa Cruz Biotechnology, Dallas, TX, USA), PDCD4
(Rockland Immunochemicals, Philadelphia, PA, USA), CX43 (Sigma), PARP
(Roche) or β-actin (Santa Cruz Biotechnology). Bound antibodies were
detected using Pierce ECL Western Blotting Substrate (ThermoFisher
Scientific, Waltham, MA).
Animal studies
Female athymic nude mice (Crl:NU(NCr)-Foxn1nu, Charles River, Frederick,
MD, USA) were obtained at 6–8 weeks of age. In all, 2 × 106 cells were
suspended in Dulbecco’s modified Eagle’s medium (DMEM) and injected
into the fourth mammary fat pad. For tumor initiation/limiting dilution
assays, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; Jackson Lab, Bar Harbor,
ME, USA) were obtained at 6–8 weeks of age. Tumor cells were suspended
in DMEM containing matrigel (50% (vol/vol)) and injected into the fourth
mammary fat pad. Tumors were measured semiweekly using digital
calipers. Tumor volume was determined by π(L1 × L22)/6 (L1, long axis; L2,
short axis), and tumor initiation was defined as ⩾ 2mm for both L1 and L2.
Animal procedures were performed under an approved protocol.
Isolation of mammary carcinoma cells from tumors
Human mammary cancer tissue was passaged as PDXs in NSG mice.
HCI-001 and HCI-002 were obtained from Alana L Welm, University of Utah,
and PEN-025 and PEN-027 were obtained from the West Virginia University
Tissue Bank. PDX tumors and tumors arising in female C3(1)/TAgmice were
harvested upon reaching a size of 1-2 cm3. To isolate mammary carcinoma
cells, tumors were minced and suspended in DMEM/F12 containing Gentle
Collagenase/Hyaluronidase (STEMCELL Technologies, Vancouver, BC,
Canada) and then processed as recommended by the manufacturer.
Briefly, tumor cell suspensions were incubated with mild agitation at 37 °C
for 15 h. Red blood cells were lysed by the addition of 0.16 M Tris-NH4Cl
(pH 7.6) and incubation at 25 °C for 3 min. Red blood cell lysis was stopped
by the addition of DMEM/F12 containing 10% fetal bovine serum . The
suspension was centrifuged and the resulting cell pellet was washed twice
with DMEM/F12 containing 10% fetal bovine serum , resuspended in
Trypsin-EDTA (0.25%; Media Tech, Corning, NY, USA) for 3 min with
disaggregation by pipette, and then washed once again. Cells were
resuspended in dispase and DNAse I (STEMCELL Technologies) at final
concentrations of 4.2 mg/ml and 192 μg/ml, respectively. The cells were
centrifuged and the cell pellet was resuspended in Hank’s balanced salt
solution containing 10mM HEPES-KOH, pH 7.2 and 2% fetal bovine serum .
Depletion of lineage-positive (Lin+) cells from prepared tumor cell
suspensions was performed using an AutoMACS sorter (Miltenyi Biotec,
San Diego, CA, USA). Briefly, cells were suspended in ice cold staining
buffer (phosphate-buffered saline supplemented with 0.5% (wt/vol) bovine
serum albumin) and blocked with 10 μg/ml mouse immunoglobulin G
(Sigma) for 15min. Cells were stained with the following biotin-conjugated
antibodies (BD Bioscience, San Jose, CA, USA): anti-mouse-CD31 (clone
390), anti-CD45 (clone 30-F11), anti-TER-119 (clone TER-119). Anti-CD140b
was from eBioscience, San Diego, CA, USA (clone APB5). Cells were washed
with labeling buffer (phosphate-buffered saline, pH 7.2 containing 0.5%
bovine serum albumin and 2mM EDTA) and incubated with streptavidin
microbeads (Miltenyi Biotec) before magnetic cell sorting as recommend
by manufacturer.
Analysis and purification of MaCSCs
For analysis of PROCR/ESA expression, cells were blocked with 10 μg/ml
normal human immunoglobulin G (R&D System, Minneapolis, MN, USA) in
ice cold staining buffer (phosphate-buffered saline supplemented with
1% (vol/vol) fetal bovine serum) for 15min. Cells were stained with
anti-human PROCR-APC (clone RCR-227; eBioscience) and anti-human
ESA-PerCP-Cy5.5 (clone EBA-1; BD Bioscience). Cells were centrifuged at
300× g for 5 min at 4 °C, and washed twice with staining buffer before
analysis.
ALDH activity was evaluated by flow cytometry using the ALDEFLUOR
assay (STEMCELL Technologies). Cell sorting or flow cytometry was
performed on a BD FACSAria using BDFACSDiva software version 6.1, or
on a BD Fortessa using BDFACSDiva software version 7.0 (Becton
Dickinson, San Jose, CA, USA). For analysis, a minimum of 10 000 events
were collected for each sample. The data were analyzed by using FCS
Express 4 Research Edition software (De Novo software, Glendale, CA, USA).
Tumorsphere formation and anoikis assays
To grow tumorspheres, 2 × 104 Lin- cells were placed in suspension cultures
in low attachment plates (Costar, Corning, NY, USA) using DMEM/F12
supplemented with B27, 4 μg/ml heparin, 20 ng/ml epidermal growth
factor, 20 ng/ml fibroblast growth factor and 1% (wt/vol) methylcellulose.
For analysis of anoikis, cells were suspended in culture as previously
described.37 Cell death was analyzed by propidium iodide staining and
flow cytometry (Invitrogen, Carlsbad, CA, USA), by Trypan blue exclusion,
or by analysis of cleaved PARP.
Expression analyses
Microarray data were extracted from GEO accessions GSE45666 and
GSE23978 and then normalized to the geometric median.90,91
For qRT–PCR, total RNA was extracted and mRNA and miR levels were
analyzed as previously described.36 Reactions were normalized to B2M or
RPLP0 for mRNA analysis, or to U6 snRNA for miR analysis. Primer
sequences are listed in Supplementary Table S2. PCR reactions were
performed on a Mx3005P Real-Time PCR System (Stratagene, La Jolla, CA,
USA). mRNA and miR levels were determined by the ΔΔCT method.
92 For
all RNA measurements, three independent experiments were performed in
duplicate manner.
Statistical analysis
Data were analyzed using either the unpaired t-test (two-tailed), or else
one-way analysis of variance followed by Tukey’s multiple comparison ad
hoc post-test. Tumor volumes were analyzed using two-way analysis of
variance with a Bonferroni post-test. Tumor initiation was analyzed using a
2 × 2 contingency table with a Fisher’s exact test. Statistical analyses were
performed in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA.
Differences were considered significant when the analysis yielded Po0.05.
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